Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy.
Brief Summary: This study aims to test the hypothesis that the artificial prolongation of the platinum-free interval with a non-platinum treatment will improve the effectiveness of overall therapy in patients with ovarian cancer progression occurring 6-12 months after first-line treatment with a platinum-derivative.


Options:
A: Arm Label: non platinum based chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: stealth liposomal doxorubicin, Drug: carboplatin, Drug: paclitaxel, Drug: Topotecan, Drug: Gemcitabine | Arm Label: platinum based chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: stealth liposomal doxorubicin, Drug: carboplatin, Drug: paclitaxel, Drug: Topotecan, Drug: Gemcitabine | Intervention Type: DRUG; Name: stealth liposomal doxorubicin; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy
B: Arm Label: Niraparib monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Niraparib-bevacizumab combination; Type: EXPERIMENTAL; Interventions: Drug: Niraparib, Drug: Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Niraparib monotherapy, Niraparib-bevacizumab combination | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Niraparib-bevacizumab combination
C: Arm Label: Arm A: Chemotherapy + Bevacizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Chemotherapy, Drug: Placebos | Arm Label: Arm B: Chemotherapy + Bevacizumab + Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Atezolizumab, Drug: Chemotherapy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo
D: Arm Label: Arm I (bevacizumab and everolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Everolimus, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (bevacizumab and placebo); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm I (bevacizumab and everolimus) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (bevacizumab and placebo)

Answer: A